Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,085.60
(
-0.45%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
98.83
(
2.18%
)
Bitcoin
77,447.76
(
-1.01%
)
News Focus
News Focus
Post# of 257438
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ciotera post# 198011

Monday, 12/07/2015 8:58:03 AM

Monday, December 07, 2015 8:58:03 AM

Post# of 257438

ABBV—10% CR [for Venetoclax] is a failure. Imbruvica probably has that much. So, it's a success as far as it's approvable based on this study, but how will it compete against Imbruvica?

Good question. Moreover, Venetoclax’s SAEs were somewhat troubling.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today